Navigation Links
Market testing of dietary supplements and drugs underscores value of USP's public health programs
Date:11/12/2007

Rockville, Md., November 12, 2007 On September 10, 2007, ConsumerLab.com issued a report stating that several multivitamin supplements did not contain label amounts of folic acid. One of these products, B-50 Tablets, manufactured by IVC, Industries, Inc., is part of U. S. Pharmacopeias (USP) Dietary Supplement Verification Program and carries the USP Verified mark. In response to the report, USP studied the verified product to confirm the announced results. USPs testing found that the B-50 Tablets do in fact contain the required amount of folic acid, as claimed on the products label. The testing also demonstrated that the tablet in question meets USP dissolution requirements. USPs analysis showed that using appropriate test methods for the type of material under assessment, as provided in the United States Pharmacopeia and National Formulary (USPNF), is key to getting accurate results.

The importance of ongoing testing of dietary supplements to a public monograph is hard to overstate, said Roger L. Williams, M.D., executive vice president and CEO of USP. For this reason, USP acknowledges ConsumerLab.coms marketplace surveillance efforts. At the same time, these efforts require careful follow-up, which USP was able to do via its USP Verified agreement with the manufacturer of the B-50 Tablets. USP understands that further studies may be conducted by manufacturers and the Food and Drug Administration (FDA) based on the September 10 report.

The USP Verified program for dietary supplements and their ingredients provides a rigorous array of tests, resulting in manufacturer and consumer confidence that whats on the label is whats in the bottle. Via its voluntary, fee-based agreements with manufacturers, USP has a continuing commitment to monitor the quality of verified ingredients and products. USP was pleased to be able to clarify some of the findings of ConsumerLab.com.

In a separate report dated October 12, 2007, ConsumerLab.com called into question the therapeutic interchangeability of two marketed extended release formulations of Buproprion Hydrochoride. For these drugs, primary responsibility for original and continuing market availability rests with the FDA working with manufacturers. USP notes that it does have drug product monographs for the involved formulations in the United States Pharmacopeia and that these monographs allow different dissolution requirements. This is appropriate on the assumption that the FDA has reviewed and found acceptable bioequivalence studies for formulations conforming to the monographs. USP does not verify drug products approved by the FDA.


'/>"/>

Contact: Sandra Kim
sek@usp.org
301-816-8241
US Pharmacopeia
Source:Eurekalert

Related biology news :

1. New study warns limited carbon market puts 20 percent of tropical forest at risk
2. Emerging (disease) markets
3. M2SYS Partners with SecuGen Corporation to Support Market Leading Hamster Plus Fingerprint Reader with Auto-On Technology
4. IEEE-USA innovation forum will help prepare US tech leaders to prosper in a global marketplace
5. Ceres and Texas A&M to develop and market high-biomass sorghum for biofuels
6. Safe water: simpler method for analyzing radium in water samples cuts testing time
7. Genetic ancestral testing cannot deliver on its promise, study warns
8. ACT Ensures Integrity of Testing Process Through Deployment of BIO-keys(R) Biometric ID Technology
9. UF scientists reveal how dietary restriction cleans cells
10. Dietary calcium could possibly prevent the spread of breast cancer to bone
11. Changing the global dietary environment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a ... point-of-care products for the objective detection of concussion and ... company has successfully completed a meeting with the U.S. ... Tbit™ blood test Pre-Submission Package. During the meeting company ... system as a precursor to commencement of a planned ...
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
(Date:11/22/2016)... MINNETONKA, Minn. , Nov. 22, 2016   ... that supports the entire spectrum of clinical research, is ... by Medical LiveWire Healthcare and Life Sciences Awards ... This award caps off an unprecedented year of recognition ... clinical trials for over 15 years. iMedNet ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... December 01, 2016 , ... Aerocom Healthcare ( http://www.aerocomhealthcare.com ... will present its chain-of-custody solution for tracking and securing medications at booth 676 ... 4-8, 2016. , Aerocom has a proven solution for tracking medications via its ...
(Date:12/2/2016)... PRUSSIA, PA (PRWEB) , ... December 01, 2016 , ... ... is through industry-wide collaboration, standardization and a beautiful technology experience. All three tenets were ... more than 100 clinical trial leaders from over 40 sponsor, CRO and site organizations ...
(Date:12/2/2016)... Boston, MA (PRWEB) , ... December 02, 2016 , ... ... of Light Event on December 3rd, 2016. The event, which is held on ... NTI’s work with helping Americans with Disabilities back into the workplace. Suitable Technologies is ...
(Date:12/2/2016)... a world leader in rapid infectious disease tests, introduced the Company,s newest product, the ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , , bioLytical was invited by the ... INSTI HIV Self Test to 350 pharmacy representatives in Nairobi ...
Breaking Biology Technology: